Flaxseed in Preventing Pneumonopathy after Radiotherapy in Patients with Metastatic Non-small Cell Lung Cancer

Inclusion Criteria

• Current diagnosis of non-small cell lung cancer (NSCLC) including patients who have metastatic disease requiring definitive thoracic and mediastinal radiotherapy with concurrent chemotherapy.
• Able to provide written informed consent and comply with all study procedures.
• Total planned radiation dose to gross disease 60-70 Gy.

Exclusion Criteria

• Current diagnosis of disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication (history of major gastrointestinal tract surgery, gastrectomy, gastrostomy, bowel resection, etc.) or history of chronic gastrointestinal disorders (ulcerative colitis, regional enteritis, or gastrointestinal bleeding).
• Known hypersensitivity to flaxseed or any of its metabolites, or wheat products.
• Taking or has taken an investigational drug within 14 days.
• Taking or has taken Amifostine or Mucomyst (N-acetylcysteine) within 14 days.
• Current or prior use of flaxseed, flax-containing products, soybeans, or soy-containing products.
• Current or prior use (limited to prior 14 days) of dietary supplements such as herbals or botanicals.
• Prior thoracic and/or mediastinal radiation therapy.